Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Abstract excerpt

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA-1273 COVID-19 vaccine or placebo. We previously assessed IgG binding antibodies to the spike protein (spike IgG) or receptor binding domain (RBD IgG) and pseudovirus neutralizing antibody 50 or 80% inhibitory dilution titer measured...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Animal Virus Infections Studies
• Share to SARS-CoV-2 and COVID-19 Research
• Share to SARS-CoV-2 detection and testing